Please assess the completion status of the following clinical trial:

Trial Title: Statin in Hip Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years old or older.~* fracture of the femoral neck or of the trochanteric mass~* undergoing surgery within 5 days for this fracture~* Signed written informed consent~Exclusion Criteria:~* contraindication to rosuvastatin:~* active liver disease including unexplained and prolonged elevations of serum transaminases and any increase of serum transaminases beyond 3 times the upper limit of normal~* severe renal impairment (creatinine clearance calculated by the formula MDRD \<30 ml / min)~* myopathy~* use of cyclosporine~* statin therapy ongoing at the admission for fracture~* curative anticoagulant therapy ongoing at the admission and expected to be maintained after the intervention~* Patients considered by the investigator to be unable to participate to the study~* Refuse to participate

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).